Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Dale Gray

Internal Medicine Rockford, IL Medical Doctor

NPI 1043252075 CMS profile 506880

2829 Glenwood Ave, Rockford, IL 61101

Open in the dashboard

General payments

$6,285

382 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Dale Gray of Rockford, IL is reported in the CMS Open Payments database as having received $6,285 across 382 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $438 24
2023 General $635 34
2022 General $1,242 74
2021 General $1,560 91
2020 General $1,188 74
2019 General $1,223 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dale Gray
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dale Gray were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dale Gray Internal Medicine median Middle half National median
2019 $1,223 $159 $48–$570 $163
2020 $1,188 $119 $33–$402 $114
2021 $1,560 $135 $37–$521 $132
2022 $1,242 $141 $42–$496 $149
2023 $635 $149 $45–$519 $160
2024 $438 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $572 35 payments
  2. AbbVie, Inc. $503 31 payments
  3. Novo Nordisk Inc $501 29 payments
  4. Pfizer Inc. $454 30 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $450 32 payments
  6. Janssen Pharmaceuticals, Inc $396 25 payments
  7. Lilly USA, LLC $370 23 payments
  8. Merck Sharp & Dohme Corporation $300 18 payments
  9. GlaxoSmithKline, LLC. $288 16 payments
  10. Sanofi-Aventis U.S. LLC $274 16 payments
  11. Other $2,176 127 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $6,178 375 payments
  2. Education $108 7 payments
Products named General payments · program years 2019–2024
  1. XARELTO $366 23 payments
  2. JARDIANCE $353 24 payments
  3. FARXIGA $300 17 payments
  4. Ozempic $272 15 payments
  5. ELIQUIS $265 14 payments
  6. TRINTELLIX $246 13 payments
  7. RYBELSUS $240 13 payments
  8. UBRELVY $218 13 payments
  9. TRELEGY ELLIPTA $217 12 payments
  10. TRULICITY $203 12 payments
  11. Other $6,016 381 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 161 drugs

Part D claims

9,922

Median for Internal Medicine: 777

Drug cost

$679,064

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 115 $128,686
Jardiance Empagliflozin Brand 87 $72,102
Xarelto Rivaroxaban Brand 54 $51,954
Trulicity Dulaglutide Brand 26 $40,680
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 26 $33,567
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 44 $29,140
Farxiga Dapagliflozin Propanediol Brand 30 $28,706
Mounjaro Tirzepatide Brand 26 $27,501
Ozempic Semaglutide Brand 25 $26,996
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 34 $20,751

The 10 drugs with the highest cost, of 161 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$27,088

Medicare's payments for the services billed

Medicare patients

259

Average age 76

Services billed

605

132 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 27%
Ischemic heart disease 27%
Chronic kidney disease 24%
Depression 22%
Heart failure 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $44
$44 — —
Wegovy
  • Novo Nordisk Inc $32
$32 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $31
$31 44 —
GEMTESA
  • Sumitomo Pharma America, Inc. $25
$25 — —
STRENSIQ
  • Alexion Pharmaceuticals, Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

382 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record